MINI FUTURE OPTIONSSCHEIN - BOSTON SCIENTIFIC | Market Closed - Börse Stuttgart 03:41:36 2024-05-23 pm EDT | ||
| 1.77 EUR | +4.73% |
|
| Current month | -16.75% | ||
| 1 month | -28.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.77 | +4.73% |
| 24-05-22 | 1.69 | +3.05% |
| 24-05-21 | 1.64 | -2.96% |
| 24-05-20 | 1.69 | -4.52% |
| 24-05-17 | 1.77 | +2.31% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JB7PM2 |
| ISIN | DE000JB7PM20 |
| Date issued | 2023-12-05 |
| Strike | 93.47 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.63 € |
|---|---|
| Lowest since issue | 1.61 € |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
75.37
USD
Average target price
81.53
USD
Spread / Average Target
+8.18%
- Stock Market
- Certificates
- Certificat
